Results 61 to 70 of about 6,313 (203)

The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design

BMC Endocrine Disorders, 2019
Background Hypoglycaemia, especially nocturnal, remains the main limiting factor of achieving good glycaemic control in type 1 diabetes. The effect of first generation long-acting insulin analogues in reducing nocturnal hypoglycaemia is well documented ...
Rikke Mette Agesen, Amra Ciric Alibegovic, Henrik Ullits Andersen, Henning Beck-Nielsen, Peter Gustenhoff, Troels Krarup Hansen, Christoffer Hedetoft, Tonny Jensen, Claus Bogh Juhl, Susanne Søgaard Lerche, Kirsten Nørgaard, Hans-Henrik Parving, Lise Tarnow, Birger Thorsteinsson, Ulrik Pedersen-Bjergaard   +14 more
doaj   +1 more source

Efficacy and safety of insulin degludec in renal transplant recipients with pre-existing diabetes

Endocrine and Metabolic Science, 2021
Introduction: Glycemic control is important in renal transplant receptions with diabetes. In the early post-transplant period, recovering renal function and concomitant steroids and immunosuppressants increase the risk of dysglycemia which adversely ...
Debmalya Sanyal, Soumyabrata Roy Chaudhuri, Anirban Majumder   +2 more
doaj   +1 more source

Once‐weekly insulin icodec versus once‐daily insulin degludec for type 2 diabetes in China: A cost‐utility and budget impact analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Insulin icodec, the first once‐weekly basal insulin analogue, was approved in China in 2024. Although it has demonstrated robust clinical efficacy, its budget impact remains unknown, and the long‐term cost‐utility within the reimbursement context needs further estimates.
Xichen Tong, Yawen Zhang, Lei Zhang, Luying Zhang   +3 more
wiley   +1 more source

Use of insulin degludec in pregnancy: two case reports and a literature review

Endocrine and Metabolic Science, 2020
As of now, insulin Degludec has no indication for use in pregnancy, because of the lack of studies that prove its safety for foetus. However it isn't infrequent that some women conceive while treating with insulin Degludec.
E. Sprio, P. Lucotti, C. Iadarola, C. Bellingeri, F. Beneventi, E. Lovati   +5 more
doaj   +1 more source

Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA [PDF]

, 2017
Article full text The full text of this article can be found here. Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please ...
Barnaby Hunt, Jakob Langer, Michelle Mocarski, William J. Valentine   +3 more
core   +2 more sources

A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear.
Alexandra Katz, Aidan Shulkin, Asmaa Housni, Amélie Roy‐Fleming, Rémi Rabasa‐Lhoret, Jean‐Francois Yale, Michael A. Tsoukas, Tricia M. Peters, Anne‐Sophie Brazeau   +8 more
wiley   +1 more source

Efficacy and safety of once‐weekly insulins in type 2 diabetes: A systematic review and meta‐analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Once‐weekly (OW) insulins represent a promising strategy to reduce injection burden and improve adherence in type 2 diabetes management. This meta‐analysis aimed to quantify pooled effect sizes for key biological and clinical outcomes, integrating new findings from the five large trials published in 2025.
Olivier Bourron, Damien Denimal
wiley   +1 more source

Pediatric diabetes: Potential for insulin degludec

Indian Journal of Endocrinology and Metabolism, 2014
Comprehensive guidelines, published recently by the International Society for Pediatric and Adolescent Diabetes (ISPAD) describe the use of insulin in children and adolescents in great detail.[1] These guidelines provide a bird's eye view of the subject, and also clarify micro management issues, which challenge the pediatric diabetes care provider from
Sanjay Kalra, Ambika Gopalakrishnan Unnikrishnan, Rakesh Sahay   +2 more
openaire   +3 more sources

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?

Clinical Medicine Insights: Endocrinology and Diabetes, 2012
The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a ...
Sami N. Nasrallah, L. Raymond Reynolds
doaj   +1 more source

Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians [PDF]

, 2018
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition that requires life-long administration of insulin. Optimal management of T1DM entails a good knowledge and understanding of this condition both by the physician and the patient.
American Diabetes Association, Bailey, Banting, Battelino, Beato-Víbora, Beck, Bergenstal, Bergenstal, Bolinder, Bolli, Boyne, Brown, Brunelle, Campbell, Choudhary, Chow, Clarke, Cox, Cox, Cranston, Cryer, DAFNE Study Group, Dandona, Danne, Davidson, Davis, de Zoysa, Diabetes Control and Complications Trial Research Group, Donnelly, Fanelli, Fokkert, Garg, Goeddel, Gogitidze Joy, Gold, Grunberger, Harris, Heise, Heller, Heller, Heller, Hepburn, Hopkins, Hutton, International Diabetes Federation, International Hypoglycaemia Study Group, Iqbal, Joy, Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Kinsley, Korzon-Burakowska, Lane, Lind, Lindholm, Little, Livingstone, Lund, Ly, Marques, Miller, Muhlhauser, Muhlhauser, Neal, Nordin, Novodvorsky, Novodvorsky, Pedersen-Bjergaard, Peters, Petrie, Petrie, Pickup, Pickup, Polonsky, Raccah, Ratner, Razavi Nematollahi, Rizza, Robinson, Rodbard, Rogers, Russell-Jones, Samann, Solini, Starostina, Tanenberg, Tattersall, Trevitt, Walford, Workgroup on Hypoglycemia, Wright, Wysham, Zaykov, Zhang, Zinman   +93 more
core   +2 more sources